

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5519962

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT
NATURE OF CONVEYANCE:	Corrective Assignment to correct the THE ADDRESS OF THE RECEIVING DATA previously recorded on Reel 034191 Frame 0150. Assignor(s) hereby confirms the THE ADDRESS WAS INCORRECTLY CHANGED.THE ADDRESS SHOULD READ: IM NEUENHEIMER FELD 584, 69120 HEIDELBERG, GERMANY.

CONVEYING PARTY DATA

Name	Execution Date
COMPLEX BIOSYSTEMS GMBH	01/02/2008

RECEIVING PARTY DATA

Name:	ASCENDIS PHARMA GMBH
Street Address:	IM NEUENHEIMER FELD 584
City:	HEIDELBERG
State/Country:	GERMANY
Postal Code:	69120

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	11993645

CORRESPONDENCE DATA

Fax Number: (212)588-0500

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 212-588-0800

Email: mroopram@haugpartners.com

Correspondent Name: HAUG PARTNERS LLP

Address Line 1: 745 FIFTH AVENUE - 10TH FLOOR

Address Line 4: NEW YORK, NEW YORK 10151

ATTORNEY DOCKET NUMBER:	519919-2001
NAME OF SUBMITTER:	JOSEPH W. TRELOAR
SIGNATURE:	/Joseph W. Treloar/
DATE SIGNED:	05/13/2019

Total Attachments: 9

source=01901632#page1.tif

source=01901632#page2.tif

source=01901632#page3.tif

source=01901632#page4.tif

source=01901632#page5.tif

source=01901632#page6.tif

source=01901632#page7.tif

source=01901632#page8.tif

source=01901632#page9.tif

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3111497

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	CHANGE OF NAME
CONVEYING PARTY DATA	
Name	Execution Date
COMPLEX BIOSYSTEMS GMBH	01/02/2008
RECEIVING PARTY DATA	
Name:	ASCENDIS PHARMA GMBH
Street Address:	TUBORG BOULEVARD 12 } Im Neuenheimer Feld 584
City:	HELLERUP } Heidelberg
State/Country:	DENMARK } Germany
Postal Code:	2900 } 69120
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	11993645
CORRESPONDENCE DATA	
Fax Number:	(212)588-0500
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2125880800
Email:	prosecutiondocketing@flhlaw.com
Correspondent Name:	FROMMER LAWRENCE & HAUG LLP
Address Line 1:	745 FIFTH AVENUE
Address Line 4:	NEW YORK, NEW YORK 10151
ATTORNEY DOCKET NUMBER:	519919-2001
NAME OF SUBMITTER:	JOSEPH W. TRELOAR
SIGNATURE:	/Joseph W. Treloar/
DATE SIGNED:	11/17/2014
Total Attachments: 4	
source=asn-1#page1.tif	
source=asn-1#page2.tif	
source=asn-1#page3.tif	
source=asn-1#page4.tif	

English translation of a German document (presented as pdf-file)

Commercial Register B of the Mannheim Amtsgericht ¹	Division B Representation of the current content of the commercial register Query from April 11, 2011, 10:54 hours page 1 of 1	Number of the company: HRB 337385
--	---	--------------------------------------

1. Number of previous entries:

2

2. a) Company:

Ascendis Pharma GmbH

b) Registered office, office, domestic business address, person authorised to receive, branch office

Heidelberg

c) Object of the Company

The object of the Company is research and development in the field of administration of bioactive substances via cleavable linkers and any activities associated therewith.

3. Share capital

EUR 49,000.000

4.) a) General rules of representation

If only one managing director has been appointed, he/she shall be sole representative of the Company. If more than one managing director has been appointed, the Company shall be represented by two managing directors jointly or by one managing director acting jointly with one employee vested with powers of attorney for the Company ("Prokurist"). Individual directors may be empowered as sole representatives of the Company.

b) Board of Management, managing body, managing directors, personally liable partners, general manager, authorized representatives, and special power of representation:

With authority to represent the Company in concluding legal transactions with himself on his own behalf or with a third party represented by him:
Managing director: Dr. Dirk Vetter, Heidelberg, born on October 13, 1963

¹ Translator's remark: Amtsgericht = local court

5. Prokura (full power of attorney):

6. a) Legal form, date of incorporation, Articles of Association or Shareholders' Agreement:

Limited liability company (GmbH)

Shareholders' Agreement dated November 18, 2002
Last amended by resolution from January 2, 2008

b) Other legal relationships

7. Date of last entry:

April 17, 2008


No. of the Company: HRB 3,
page 1 of 1

Query from April 11, 2011, 10:56 hours

Commercial Register B of the Mannheim Amtsgericht

Number of entry	a) Company b) Registered office, office, domestic business address, person authorised to receive, branch office c) Object of the Company	Share capital	General rules of representation a) Board of Management, managing body, managing directors, personally liable partners, general manager, authorized representatives, and special power of representation	Prokura (full power of attorney)	Legal form, date of incorporation, Shareholders' Agreement b) Other legal relationships	Date of entry b) Remarks
1	2	3	4	5	6	7
1	a) <u>Complex BioSystems GmbH</u> b) Heidelberg c) <u>Research and development of chemical processes for the optimization of biological macromolecules</u>	EUR 49,000.00	a) If only one managing director has been appointed, he/she shall be sole representative of the Company. If more than one managing director shall be appointed, the Company shall be represented by two managing directors jointly or by one managing director acting jointly with one employee vested with powers of attorney for the Company ("Prokurist"). Individual directors may be empowered as sole representatives of the Company. b) Managing director: Dr. Dirk Vetter, Heidelberg, born on October 13, 1963, with authority to represent the Company in concluding legal transactions with himself on his own behalf or with a third party represented by him.		a) Limited liability company (GmbH) Shareholders' Agreement dated November 18, 2002, last amended by resolution from January 1, 2008	a) February 20, 2006 Pallmann b) This sheet was transferred to and updated on an IT system and thus replaces the previous register sheet. Date of release: February 20, 2006. Date of first entry: November 22, 2002. Shareholders' Agreement: special volume, sheet 325 et. seq. Amendment resolution: special volume, sheet 265 et. seq.

2	<p>a) Company name changed to: Ascendis Pharma GmbH</p> <p>b) Object of the Company changed to: Research and development in the field of administration of bioactive substances via cleavable linkers and any activities associated therewith</p>		<p>a) On January 2, 2008, the shareholders' meeting decided to amend the following sections of the Shareholders' Agreement: sec. 1, para. 1 (Name and registered office), sec. 2, para. 1 (Object of the Company), sec. 4 (Announcements), sec. 5, para. 1 (Nominal capital), sec. 7, para. 5 (Shareholders' meeting), sec. 8, para. 2 (Business for which the shareholders' meeting is responsible), sec. 9 (Shareholder resolutions), sec. 11 (Company directors), sec. 14 (Appropriation of profits), sec. 16 (Budget, previously rights to be given information, duty to inform), and sec. 35 (Non-compete clause); in addition, shareholders decided to delete sections 6, 10, 17 and sections 32 to 34 without replacement.</p> <p>Several sections were renumbered: sections 7-9 became sections 6-8, sections 11-16 became sections 10-14, section 33 became section 15, and sections 35-36 became sections 16-18.</p>	<p>a) April 17, 2011 Ley</p>
---	---	--	--	----------------------------------



Jork, May 17, 2011

This is to certify that the foregoing is a true and complete translation of the German text

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Dirk Vetter	02/08/2008
Harald Rau	02/08/2008
Thomas Wegge	02/08/2008
Ulrich Hersel	02/08/2008
RECEIVING PARTY DATA	
Name:	Complex BioSystems GmbH (the name was change to Ascendis Pharma GmbH)
Street Address:	Im Neuenheimer Feld 584
City:	Heidelberg
State/Country:	GERMANY
Postal Code:	69120
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	11993645
CORRESPONDENCE DATA	
Fax Number:	(212)588-0500
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	(212) 588-0800
Email:	dgamache@flhlaw.com
Correspondent Name:	FROMMER LAWRENCE & HAUG
Address Line 1:	745 FIFTH AVENUE- 10TH FL.
Address Line 4:	NEW YORK, NEW YORK 10151
ATTORNEY DOCKET NUMBER:	519919-2001
NAME OF SUBMITTER:	Danielle Gamache

CH \$40.00 11993645

Total Attachments: 2
 source=00523749#page1.tif

501210171

PATENT
REEL: 024565 FRAME: 0711
PATENT
REEL: 049160 FRAME: 0677

INVENTION/PATENT APPLICATION ASSIGNMENT
FROM INVENTOR(S) TO COMPANY

WHEREAS I/WE Dirk VETTER of Werderstrasse 46, 69120 Heidelberg, Germany, Harald RAU of Lindenweg 5/4, 69126 Heidelberg, Germany, Thomas WEGGE of Am Pferchelhang 30, 69118 Heidelberg, Germany and Ulrich HERSEL of Fritz-Frey-Strasse 2, 69121 Heidelberg, Germany, respectively, have made a certain new and useful invention as set forth in an application for United States Letters Patent, entitled: **ALIPHATIC PRODRUG LINKER** executed by us on the date of execution of this document, as shown below, and filed concurrently herewith; OR

for which an application for United States Letters Patent was filed on **12/21/07**, and identified by United States Serial No. **11/933,645**;

AND WHEREAS, **Complex BioSystems GmbH**, having an address of **Im Neuenheimer Feld 584, 69120 Heidelberg, Germany**; hereinafter referred to as assignee, is desirous of acquiring the entire right, title and interest in and to said invention and in and to any and all Letters Patent of the United States and foreign countries that may be obtained therefore;

NOW, THEREFORE, for good and valuable consideration, the receipt for and sufficiency of which is hereby acknowledged, We do hereby sell, assign, transfer and set over unto said assignee, its legal representatives, successors, and assigns, the entire right, title and interest in and to said invention as set forth in the above-mentioned application, including any continuations, continuations-in-part, divisions, reissues, re-examinations or extensions thereof, and in and to any and all patents of the United States and foreign countries that may be issued for said invention;

UPON SAID CONSIDERATIONS, We hereby agree with the said assignee that We will not execute any writing or do any act whatsoever conflicting with these presents, and that We will, at any time upon request, without further or additional consideration but at the expense of said assignee, execute such additional assignments and other writings and do such additional acts as said assignee may deem necessary or desirable to perfect the assignee's enjoyment of this grant, and render all necessary assistance in making application for and obtaining original, divisional, continuations, continuations-in-part, reexamined, reissued, or extended Letters Patent of the United States or of any and all foreign countries on said invention, and in enforcing any rights or causes of action accruing as a result of such applications or patents, by giving testimony in any proceedings or transactions involving such applications or patents, and by executing preliminary statements and other affidavits, it being understood that the foregoing covenant and agreement shall bind, and inure to the benefit of the assigns and legal representatives of assignor and assignee;


Assignment Continued
Aliphatic prodrug linker

AND We request the Commissioner of Patents and Trademarks to issue any Letters Patent of the United States that may be issued for said invention to said assignee, its legal representatives, successors or assigns, as the sole owner of the entire right, title and interest in and to said patent and the invention covered thereby.

FEB 08, 2008
Date:


Signature: Dirk VETTER

Feb 08, 2008
Date:


Signature: Harald RAU

Feb 08, 2008
Date:


Signature: Thomas WEDGE

Feb 08, 2008
Date:


Signature: Ulrich HERSEL